Regulatory matrix
91 published regulatory records. Each cites an official source and the date it was checked. A regulatory status says what one regulator recorded for one scope. It is not evidence of efficacy or safety, and one jurisdiction’s action does not apply in another. Pairs marked “No published record” mean only that WPF has published nothing for that jurisdiction. They do not mean no regulatory action exists or that a review is scheduled. Product or formulation is shown as “Not recorded” because the record does not capture it. The action label comes from the linked official source, not from the jurisdiction name.
8 rows
| Peptide | Jurisdiction | Regulator | Product or formulation | Scope | Action | Linked source | Date checked |
|---|---|---|---|---|---|---|---|
| Elamipretide | European Union | EMA | Not recorded | EMA orphan designation is not marketing authorization; no EU marketing authorization was identified in the reviewed official record. | No approval recorded | EMA orphan designation EU/3/21/2430Linked source: www.ema.europa.eu | 2026-09-09 |
| Elamipretide | United States | FDA | Not recorded | Improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg. | Approval recorded | FDA accelerated approval announcementLinked source: www.fda.gov | 2026-09-09 |
| Elamipretide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |